Last reviewed 2026-04-20 · How we verify

Quetiapine Fumarate Tablets 25 mg

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Headache
• COVID-19
• Dry mouth
• Fatigue
• Somnolence
• Dizziness
• Nasopharyngitis
• Upper respiratory tract infection
• Sleep disorder
• Vertigo
• Sedation
• Anxiety

Key clinical trials

• A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression (PHASE2)
• A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard (PHASE1)
• Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
• Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine (PHASE2)
• Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions (NA)
• Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions (NA)
• Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions (PHASE1)
• Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Quetiapine Fumarate Tablets 25 mg CI brief — competitive landscape report
• Quetiapine Fumarate Tablets 25 mg updates RSS · CI watch RSS
• IPCA Laboratories Ltd. portfolio CI